Sign up to save your podcasts
Or
Share Updates on Breast Cancer Treatment: Exploring CDK4/6 Inhibitors & Endocrine Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Updates on Breast Cancer Treatment: Exploring CDK4/6 Inhibitors & Endocrine Therapy
Host: Pavani Chalasani, MD, MPH
Guest: Kevin Kalinsky MD, MS
CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.
View all episodes
By ReachMD
4.5
22 ratings
Host: Pavani Chalasani, MD, MPH
Guest: Kevin Kalinsky MD, MS
CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.